In Data Release 33, the GDC released data from two new projects at the GDC:
- NCI’s Exceptional Responders Initiative, which set out to understand why some patients have unexpected and long-lasting responses to treatment. A variety of cancer types including glioblastoma, breast cancer, and colorectal cancer are included.
- NCI’s Molecular Profiling to Predict Response to Treatment (MP2PRT) Program to characterize samples collected from NCI-sponsored clinical trials in order to help predict which therapies will benefit specific patients. This first batch of data contains Wilms Tumor samples.
DR 33 also includes additional methylation data for TARGET and CGCI programs. For details, please visit the GDC Data Release Notes.